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ABSTRACT

Background: Vascular endothelial growth factor (VEGF) has two prominent biological effects of inducing mitogenesis and
migration of vascular endothelial cells and to produce permeability on the microvasculature. Epidermal growth factor (EGF),
known by its mitogenic activity on different types of cells, could induce the proliferation and differentiation of the epithelial
cells and stimulate its regeneration. Doxorubicin (DXR) is a widely used anticancer drug and is one of most commonly used
chemotherapeutic drugs, however it may cause some serious complications such as toxicity in various tissues in the body.
Aims: The present study aims to investigate the effect of EGF on the VEGF immunoexpression in submandibular salivary
gland tissue of rats receiving Doxorubicin (DXR).
Methods and Material: 30 male Albino rats, two months old and weighing 200-250 gm body weight, were divided equally
into three groups as follows: Group I (control group). Group II: rats received 20 mg/kg body weight DXR as a single
intra peritoneal injection. Whereas, group III: rats received the same dose of DXR and on the next day they were injected
intraperitoneally with EGF in a daily dose of 10µg/kg body weight for 7 consecutive days.
Submandibular salivary glands were dissected out and processed for histological investigation and immunohistochemical
localization of VEGF in the glandular tissue.
Statistical analysis used: ANOVA was used to compare the mean area percentage of VEGF immunostaining among the
specimens of different groups followed by Tukey’s Multiple Comparison Test.
Results: VEGF expression in submandibular salivary glands of rats significantly decreased after DXR injection. However,
daily intraperitoneal injections of EGF restored normal levels of VEGF expression in the glandular tissue.
Conclusions: EGF preserved glandular architecture after DXR injection and consequently the immunohistochemical
expression of VEGF in the glands to approximately the normal level.
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INTRODUCTION

and mammary epithelial cells. It is synthesized in several
organs as the salivary glands, kidneys, lactating mammary
glands, small intestine, liver and pancreas[5-7].

Growth factors are protein molecules synthesized by
the body that regulate many aspects of cellular functions.
Vascular endothelial growth factor (VEGF) are a family
of secreted growth factors and are considered to be a
powerful angiogenic factor that acts specifically on vascular
endothelial cells. Two important biological properties of
VEGF are its ability to induce mitogenesis and migration
of vascular endothelial cells and to produce permeability
on the microvasculature more potently than histamine and
its expression and production were found influenced by
numerous and diverse factors[1-4].

The interaction of the EGF with its receptor on the
fibroblasts and epidermal cells results in the stimulation of
cell proliferation across wounds. This biological activity has
encouraged the development of recombinant growth factors
which enhanced the healing capacity of acute and chronic
wound healing[8-10].
Doxorubicin (DXR) is a widely used anticancer drug
and is one of most commonly used chemotherapeutic drugs.
However, it shows some serious adverse effects such as the
significant toxicity that can occur not only during, but also
years after treatment[11,12].

Growth factors have a vital role during wound healing
by contributing to different patterns of cell activation and of
the prominent growth factors is the Epidermal growth factor
(EGF). EGF is known by its mitogenic activity on different
types of cells like epidermal cells, fibroblasts, muscle cells

Jensen, et al., 2003[13] studied the effect of chemotherapy
on the salivary gland of patients with different types of
cancers. Apart from xerostomia, the salivary glands of almost

Personal non-commercial use only. EJH copyright © 2021. All rights served

418

DOI: 10.21608/ejh.2020.31011.1299

Mansy et al.,

half of the patients showed many pathological changes such
as degeneration of the cells of the acini and ducts as well as
inflammatory cells infiltration. Also, degenerated salivary
glands were markedly detected less than 2 weeks after
chemotherapy.
The protective role of EGF against the destructive effect
of anticancer drug Doxorubicin on the salivary gland tissues
has not been investigated before and the thus the present
study was designed to investigate the effect of EGF injection
on the VEGF immunoexpression in submandibular S.G. of
rats receiving DXR.
SUBJECTS AND METHODS
This study was approved by the Ethics committee,
Faculty of Dentistry, Cairo University. Thirty male adult
albino rats, two months old, pathogen free of average weight
200 gm were used. The animals were housed in controlled
environment (temperature 25o ± 2 0C, humidity 70 -80 %
and 12hr dark/light cycle). The rats were equally divided into
three groups. These groups were categorized as follows:

Fig. 1: Showing an example of calculation of VEGF area percentage
expression

Image analysis data representing experimental values
of VEGF immunostain were given as mean and standard
deviation. ANOVA (ONEWAY ANOVA test, n=10, P < 0.05)
was used to compare the mean area percentage of VEGF
immunostaining among the specimens of different groups.
This has been followed by Tukey’s Multiple Comparison
Test (Post Hoc Tukey HSD), using SPSS 25.0 for Windows
(SPSS Inc., Chicago, IL, USA) to perform a pair-wise
comparison between each group versus the other[15].

Control Group
The rats were kept on the normal control diet and
subjected to intraperitoneal injection of 9% saline and did
not receive DXR or EGF.

Doxorubicin Group (DXR gp)

RESULTS

The rats received 20 mg/kg body weight Doxorubicin
(DXR) as a single intra-peritoneal injection[14].

Histological examination of submandibular salivary
gland of rat of control group revealed its main structural
components composed of parenchymal tissue supported
by connective tissue stroma containing the blood vessels
and nerves. The secretory acini were numerous, rounded
in shape, small in size and exhibited narrow lumen. They
appeared lined by pyramidal cells having deep basophilic
cytoplasm. Their nuclei were rounded. The striated ducts
were clearly recognized and appeared lined with a single
layer of columnar cells having centrally placed vesicular
nuclei and intense eosinophilic cytoplasm. The granular
convoluted tubules appeared folded and lined by columnar
cells having basally situated nuclei. They were packed
apically with acidophilic granules (Figure 2A).

Epidermal growth factor Group (DXR + EGF)
The rats received the same intraperitoneal dose of DXR
(20 mg/kg body weight) and on the next day they were
injected intra-peritoneally by 10µg/kg body weight of EGF
provided by Sigma-Aldrich, Inc. for 7 consecutive days[5].
At the end of the experimental procedures , animals were
sacrificed by euthanization and their submandibular salivary
glands were dissected out. The glands were then processed
for histological examination by hematoxylin and eosin
(H&E) staining and immunohistochemical localization of
VEGF using staining reaction incubated by anti-VEGF.

Glandular histological sections of rats treated with
DXR showed several pathological changes. The secretory
acini appeared with massive cytoplasmic vacuolization.
Deformation in the acini and loss of normal cellular
orientation were frequently encountered. Moreover, some
acini displayed complete degeneration of their secretory cells.
Increase inflammatory response in the form of increased
inflammatory cells was evident. A clear space separated the
parenchymal elements which might be an index of interstitial
edema and extravasated RBCs in between acini and ducts
(Figure 2B).

Measurement of area percentage of positive cells was
done in the form of an area and area percent inside a standard
measuring frame of an area 114342.9 mm2 per 10 fields from
different slides using a magnification of 400X by the light
microscope transferred to the monitor. Areas containing the
most uniformly stained tissues were chosen for evaluation.
These areas were masked by red color and analyzed using
Image J (1.46 a, NIH, USA) computer system (Figure 1).
Values were presented as mean and standard deviation values
and statistically analyzed.
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As compared to the histological findings of DXR group,
the glandular tissues of rats of the DXR+EGF group showed
great improvement in the architectural features of the
glands. No evidence of an increased inflammatory condition
was noticed. On the other hand, multiple blood vessels
engorged with RBCs were detected in association with the
striated ducts. Moreover, a rich vascular network was found
in close vicinity to the excretory ducts and circumscribed
them (Figure 2C).

Fig. 3: A. Photomicrograph of submandibular salivary gland of rat of
control group showing +ve VEGF expression in the striated ducts, granular
convoluted segments and few nuclei of the secretory acini (DAB, orig. mag.
X400).

The submandibular salivary glands of rats of the control
group showed +ve cytoplasmic immunoreactivity to VEGF
in the secretory acini, duct system and blood vessels
(Figures 3A ,4A). On the other hand, the immunohistochemical
findings of DXR group corroborated with the histological
results where VEGF protein expression in the DXR group
was evidently different from that of the control group.

B. Photomicrograph of submandibular salivary gland of rat of DXR group
showing a noticeable decrease in VEGF immuno-expression in the glandular
tissue (DAB, orig. mag. X400).
C. Photomicrograph of submandibular salivary gland of rat of DXR+EGF
group showing a generalized increase in the expression of VEGF in the
parenchymal tissue of the glands (DAB, orig. mag. X400).

The VEGF immunoreactivity in the submandibular
salivary glands of rats of DXR group obviously
decreased in the parenchymal elements of the glands and
-ve immunoexpression of VEGF in the blood vessels
(Figures 3B,4B). A statistically significant decrease in the
mean area percent of VEGF expression was recorded when
comparing control and DXR groups with p=0.003 (Table 1).
The glandular sections of rats of (DXR+EGF) group
revealed a surge in the anti-VEGF antibody expression in
the parenchymal tissue of the glands to an extent similar
or slightly exceeding that of the control group (Figure
3C). Moreover, the blood vessels showed positive reaction
to VEGF that was negative in the previous group of DXR
(Figure 4C).

Fig. 4: A. Photomicrograph of submandibular salivary gland of rat of
control group showing +ve VEGF immunoreactivity in the blood vessels
(DAB, orig. mag. X400).
B. Photomicrograph of submandibular salivary gland of rat of DXR group
showing -ve immunoexpression of VEGF in the blood vessels (DAB, orig.
mag. X400).
C. Photomicrograph of submandibular salivary gland of rat of DXR+EGF
group showing positive immuno-expression of VEGF in the blood vessels
(DAB, orig. mag. X400).

On the other hand, Post Hoc Tukey HSD test, comparing
each two group revealed no significant difference between
the control group and (DXR+EGF) group (p=0.253).
However, a significant decrease was recorded between the
control and DXR gp (p=0.008) and a significant increase was
recorded between DXR and (DXR+EGF) group (p=0.0001)
(Table 2, Chart 1).

Table 1: Area Percentage of VEGF immuno-expression in different
groups
Groups

Control

DXR

DXR
+
EGF

Minimum

3.80

2.88

5.49

Median

6.12

3.33

7.68

Maximum

7.73

4.02

8.73

Mean

6.05

3.40

7.40

Standard Deviation

1.49

0.42

1.25

Standard Error

0.67

0.19

0.56

P- value

0.003

Table 2: Tukey’s Post Hoc Test for VEGF immuno-expression in
different groups

Fig. 2: A. Photomicrograph of submandibular salivary gland of rat of
control group showing regular gland architecture (H&E, orig. mag. X400).
B. Photomicrograph of submandibular salivary gland of rat of DXR group
showing degenerated acini with multiple vacuoles extravasated RBCs in
between acini and ducts (H&E orig. mag. X400).

Tukey’s Multiple comparison

P-value

Control vs DXR

0.008*

Control vs DXR+EGF

C. Photomicrograph of submandibular salivary gland of rat of DXR+EGF
group showing well aligned acini together with blood vessels engorged with
RBCs in association with the striated ducts exhibiting good cell alignment
and minute areas of small vesicles (H&E orig. mag. X400).

DXR vs DXR+EGF
* Significant at p<0.05
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of EGF on intestine from ischemia/reperfusion injury. They
noticed the marked decrease of inflammatory infiltrates
(mainly neutrophils) in the intestine of the EGF treated
animals. They also registered decreased level of TNF-α (a
major pro-inflammatory cytokine) which may contribute to
the cytoprotective effect.
The healing potential of EGF was documented in several
studies. It was prevalent in epithelial cell proliferation,
migration, re-epithelialization and regeneration of gastric
glands during renal epithelium regeneration[20], gastric ulcer
healing[21] and corneal epithelium[22].
Administration of exogenous EGF in a neonatal
rat necrotizing enterocolitis (NEC) model reduced the
expression of pro-inflammatory mediators and at the same
time upregulated production of anti-inflammatory cytokine
in the ileum[23]. Moreover, EGF was found to be of clinical
importance in the prevention as well as treatment of NEC.
It helped to increase healing after inflammation, to decrease
bacterial translocation and restore function[24].

Chart 1: Bar chart showing the area percent of VEGF immune-expression
in submandibular gland of all groups

DISCUSSION
Doxorubicin (DXR) is a highly effective chemotherapeutic
agent, interfering with the growth of cancer cells by blocking
topoisomerase-2 enzyme needed for division of these cells.
The DXR chemical structure cause the formation of free
radicals intracellularly which in turn induces the generation
of oxidative stress. These formed oxidative stress is directly
correlated to cellular destruction[16]. Moreover, DXR also
causes an imbalance between free oxygen radicals and
antioxidants. The main function of the antioxidants is to
combat the free oxygen radicals to prevent cellular injury,
so any decrease in the antioxidants or increase in the amount
of free radicals will shift the body from a state of health to
a state of pathology. This disturbed oxidant–antioxidant
system results in tissue damage that is evident with lipid
peroxidation and protein oxidation in tissue[17].

The results of the current study can be explained by the
EGF binding to its receptor EGFR which subsequently leads
to activation of pathways that are involved in regulating
cellular activities such as proliferation and differentiation.
This also explains the role of EGF in facilitating epidermal
cell regeneration and in the process of dermal wound healing
through stimulating the proliferation and migration of
keratinocytes[25].
The VEGF immunoreactivity in the glandular tissues of
rats of DXR group obviously decreased in the parenchymal
elements of the glands. These results were statistically
confirmed where a significant reduction in the mean area
percent of VEGF expression was found when comparing
control and DXR groups with p<0.01.The decrease of this
angiogenic factor in the submandibular salivary glands of
DXR group was found consistent with the histopathological
finding of the generalized decrease of vasculature in the
glandular tissue. Duyndam, et al., 2007[26] concluded that
DXR can repress VEGF expression by inhibiting hypoxia
inducible factor 1 (HIF-1) through different mechanisms.

The results of the present study indicated that the
systemic injection of DXR in rats resulted in pathological
structural alterations within the submandibular S.G. tissue.
Atrophied and degenerated acini with multiple cytoplasmic
vacuolization were detected.
The frequently observed intracytoplasmic vacuolizations
in both the acinar and ductal cells might be caused mainly
by mitochondria. This is explained by the fact that sodium
ions enters the cells profusely due to failure of cellular
metabolism. This profusion causes an osmotic effect which
induces breakdown of the macromolecules found in the
injured cell and subsequently presence of the vacuoles.
Moreover, the intracytoplasmic vacuolations had also been
explained by deterioration of other cell organelles specially
the Golgi apparatus, that if acquiring fatty nature they
appeared as vacuoles[18].

Merighi, et al., 2009[27] explained such mechanisms
by indicating that treatment with DNA damaging drug like
DXR resulted in increase in the proangiogenic cytokine
interleukin-8 (IL-8) and downregulation in the production
of hypoxia inducible factor 1α (HIF-1α) which sequentially
decrease the expression of VEGF. Furthermore, they
registered that DXR could affect the adenosynergic signaling
through blockage of different receptors such as A3 receptors
which could be the cause of more decrease of VEGF
expression. Moreover, Kawagishi, et al., 2001[28] approved
that DXR significantly decreased the VEGF expression into
human melanoma cells after 24 hour of injection and they
insisted about future treatment schedules including agents
that target the HIF-1α signaling pathway.

The submandibular S.G. of rats treated with DXR and
EGF showed great improvement in the gland architecture.
Resolution of vacuolar degeneration was noted apart from
minute areas of microvesicles found in the parenchymal
tissue. Cells of both the acini and ducts appeared to be
histologically similar to those of the control group.
The anti-inflammatory response of EGF was evident
in the current work and confirmed previously conducted
studies. Berlanga, et al., 2002[19] recorded a protective effect

The immunoexpression of VEGF in the DXR and EGF
group was nearly at the same level as in the control group
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and a statistically non-significant difference was found
comparing both groups. Thus furtherly indicating the role of
EGF in counteracting the oxidative stresses caused by DXR
in the submandibular salivary glands.

endothelial growth factor. The Journal of biological
chemistry. 1996;271(2):736-41.

Similar results were found in other studies which showed
that EGF restored normal levels of cytokeratin expression in
the submandibular glands of diabetic rats[29] as well as myosin
levels in submandibular glands of rats receiving Botulinum
toxin[30]. Cytokeratin and myosin levels are indications of
the healing capacity of the epithelial cells to proliferate and
regenerate. Both proteins showed an immunohistochemical
expression similar to their controls after EGF injection.
These studies showed that EGF has the ability to counteract
the deleterious effect of the production of oxidative stresses
caused by diabetes and Botulinum toxin. The previous
studies comes in agreement with the results of the current
study.
Moreover, Yamawaki, et al., 2010
stated that the
addition of EGF and nerve growth factor to culture media
containing epithelial rests of Malassez collected from
porcine periodontal ligament increased the expression of
VEGF. Also, EGF and transforming growth factor-β (TGFβ)
have been shown to induce VEGF expression in cell culture
models[32].

4.

Deroanne CF, Hajitou A, Calberg-Bacq CM, Nusgens
BV, Lapiere CM. Angiogenesis by fibroblast growth
factor 4 is mediated through an autocrine up-regulation
of vascular endothelial growth factor expression. Cancer
research. 1997;57(24):5590-7.

5.

Ohlsson B, Jansen C, Ihse I, Axelson J. Epidermal growth
factor induces cell proliferation in mouse pancreas and
salivary glands. Pancreas. 1997;14(1):94-8.

6.

Buret A, Olson ME, Gall DG, Hardin JA. Effects
of orally administered epidermal growth factor on
enteropathogenic Escherichia coli infection in rabbits.
Infection and immunity. 1998;66(10):4917-23.

7.

Iwase N, Sasaki T, Oshiro T, Tamada T, Nara M,
Sasamori K, et al. Differential effect of epidermal
growth factor on serous and mucous cells in porcine
airway submucosal gland. Respiratory physiology &
neurobiology. 2002;132(3):307-19.

8.

Servold SA. Growth factor impact on wound
healing. Clinics in podiatric medicine and surgery.
1991;8(4):937-53.

9.

Lee SW, Jung KI, Kim YW, Jung HD, Kim HS,
Hong JP. Effect of epidermal growth factor against
radiotherapy-induced oral mucositis in rats. International
journal of radiation oncology, biology, physics.
2007;67(4):1172-8.

[31]

We concluded that EGF has a cytoprotective and reparative
effect against DXR induced changes on the S.G. tissue. DXR
injection significantly decreased to VEGF immunoexpression
in the glandular tissue. However, exogenous EGF preserved
the immunohistochemical expression of VEGF in the glands
or restored it to approximately the normal level.

10. Lee KK, Jo HJ, Hong JP, Lee SW, Sohn JS, Moon SY,
et al. Recombinant human epidermal growth factor
accelerates recovery of mouse small intestinal mucosa
after radiation damage. International journal of radiation
oncology, biology, physics. 2008;71(4):1230-5.

KEY MESSAGES
Systemic injection of DXR in rats resulted in pathological
structural alterations within the submandibular S.G. tissue.
Submandibular salivary gland of rats treated with DXR and
followed by EGF showed great improvement in the gland
architecture. Resolution of vacuolar degeneration was noted
apart from minute areas of microvesicles detected in the
parenchymal tissue.
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effects of erdosteine against doxorubicin-induced
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الملخص العربى

تأثير عامل نمو البشرة على تعبير عامل النمو البطاني الوعائي على الغدة اللعابية تحت
الفك السفلي للجرذان البيضاء التي تتلقى الدوكسوروبيسين
محمد منسي ،١ملك سليمان ،٢رياب مبارك ،٢محمد شامل

٣

١كلية طب االسنان ،جامعة جازان ،المملكة العربية السعودية
قسم بيولوجيا الفم ،كلية طب االسنان٢ ،جامعة القاهرة٣ ،الجامعة البريطانية في مصر

المقدمه :عامل النمو البطاني الوعائي له تأثيران بيولوجيان بارزان للحث على االنقسام وهجرة الخاليا البطانية الوعائية
وإنتاج نفاذية على األوعية الدموية الدقيقة .يمكن لعامل نمو البشرة  ،المعروف بنشاطه االنقسامي على أنواع مختلفة من
الخاليا  ،أن يحفز تكاثر الخاليا الظهارية وتمايزها ويحفز تجديدها .دوكسوروبيسين هو دواء مضاد للسرطان يستخدم
عا  ،إال أنه قد يسبب بعض المضاعفات الخطيرة مثل التسمم
على نطاق واسع وهو أحد أكثر أدوية العالج الكيميائي شيو ً
في أنسجة مختلفة في الجسم.
الهدف من الدراسة :تهدف الدراسة الحالية إلى التحقق من تأثير عامل نمو البشرة على التعبير المناعي لعامل النمو
البطاني الوعائي في أنسجة الغدد اللعابية تحت الفك السفلي للفئران التي تتلقى دوكسوروبيسين .
طرق و مواد البحث 30 :ذكور جرذ ألبينو عمر شهرين ووزن  250-200جم قسمت بالتساوي إلى ثالث مجموعات
على النحو التالي :المجموعة األولى (المجموعة الضابطة) .المجموعة الثانية :تلقت الفئران  20مجم  /كجم من وزن
الجسم دوكسوروبيسين كحقنة واحدة داخل الصفاق .في حين أن المجموعة الثالثة :تلقت الجرذان نفس الجرعة من
دوكسوروبيسين وفي اليوم التالي تم حقنها داخل الصفاق مع عامل نمو البشرة بجرعة يومية  10ميكروجرام  /كجم من
وزن الجسم لمدة  7أيام متتالية.
في نهاية التجربة تم التضحية بالفئران واستخراج الغدة اللعابية تحت الفكية لفحصها مجهريا ً و للفحص المناعي.
النتائج :انخفض تعبير عامل النمو البطاني الوعائي في الغدد اللعابية تحت الفك السفلي بشكل ملحوظ بعد حقن
دوكسوروبيسين .ومع ذلك  ،فإن الحقن اليومية داخل الصفاق من عامل نمو البشرة أعادت المستويات الطبيعية لتعبير
عامل النمو البطاني الوعائي في األنسجة الغدية.
االستنتاجات :حافظ عامل نمو البشرة على البنية الغدية بعد حقن دوكسوروبيسين وبالتالي التعبير الكيميائي المناعي لـ
عامل النمو البطاني الوعائي في الغدد إلى المستوى الطبيعي تقريبًا.
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